摘要
目的:探讨重组人血管内皮抑制素(恩度)对人肝癌细胞SMMC-7721VEGF165b表达的影响,及上调VEGF165b表达后,SMMC-7721对恩度敏感性的变化。方法:采用RT-PCR法和蛋白质印迹法检测恩度干预SMMC-7721后VEGF165b的表达变化;稳定转染VEGF165b真核表达质粒到SMMC-7721,RT-PCR和免疫细胞荧光共聚焦显微镜检测VEGF165b、HIF-1α和下游靶基因VEGFA表达的变化;MTT法检测恩度对人肝癌细胞生长抑制率的影响。结果:100和400μg/mL恩度能够诱导VEGF165b mRNA和蛋白表达上调,而外源性VEGF165b下调HIF-1α及下游靶基因VEGFA的表达。转染空质粒后,500和1000μg/mL恩度引起SMMC-7721的生长移植率分别为1.6%和0.4%,转染VEGF165b后,500μg/mL和1000μg/mL恩度引起的生长移植率分别为8.5%(P=0.0000)和20.2%(P=0.0000)。结论:恩度抗肿瘤新生血管的作用部分是通过上调VEGF165b介导的,VEGF165b增加SMMC-7721细胞对恩度的敏感性,两者治疗肿瘤有协同作用。
OBJECTIVE:To investigate the impact of endostar on the expression of VEGF165b,and determine the effect of VEGF165b for he sensitivity of tumor cell to endostar. METHODS:The expression of VEGF165b of SMMC-7721 was detective by RT-PCR and Western Blotting after treated with endostar. After transfected with VEGF165b,the expression of HIF-1α and its downstream target genes VEGFA was analyzed by RT-PCR and Immunofluorescent confocal microscopy. SMMC-7721 cell was transfected with VEGF165b or empty vector,and then treated with endostar,the cell growth inhibiting rate was detected by methly thiazolyl tetrazolium (MTT). RESULTS:High dose endostar at 100 and 400 μg/mL up-regulated the expression of VEGF165b,while VEGF165b suppressed the expression of HIF-1α and its downstream target genes VEGFA. After transfection with empty-vector,treatment of SMMC-7721 cell with 500 and 1 000 μg/mL endostar induced the tumour cell growth inhibiting rate at 1.6% and 0.4% individually. After transfection with VEGF165b,treatment of SMMC-7721 cell with 500 and 1 000 μg/mL endostar induced the tumour cell growth inhibiting rate at 8.5% (P=0.000 0) and 20.2%( P=0.000 0) individually. CONCLUSIONS:Endostar can inhibite tumour growth and anti-angiogenisis partly via VEGF165b,and VEGF165b sensitize the tumour cell to endostar. VEGF165b and endostar have synergistic effect on tumor suppression.
出处
《中华肿瘤防治杂志》
CAS
2010年第1期37-40,49,共5页
Chinese Journal of Cancer Prevention and Treatment
关键词
内皮抑素类
血管内皮生长因子
肝肿瘤
endostatins
vascular endothelial growth factor
liver neoplasms